DEMYELINATION IS the partial or total loss of the myelin sheath of nerve fibers following normal myelin development. Multiple sclerosis (MS) is the most common acquired inflammatory demyelinating disease of the central nervous system. The presumed immune-mediated nature of demyelinating diseases prompted evaluation of immunomodulatory and immunosuppressive agents for their treatment. The management of demyelinating diseases, in particular MS, has evolved significantly during the last decade. This has shifted the emphasis from treatment of acute relapses and management of symptoms to pharmacotherapy aimed at altering the natural history of the disease. Current relapse therapy, with glucocorticoids, had its origin in the 1950s and is used to accelerate recovery with no clear impact on the degree of improvement from acute neurologic dysfunction. For more than 100 years, symptom management has used unapproved or off-label uses of agents, with their expected benefit based on anecdotal reports or small case series. These interventions, although successful in improving the quality of life of patients with MS, did not alter the natural history of MS.1 The ability to favorably modify the number of relapses of MS began in 1993 when interferon beta-1b was approved by the Food and Drug Administration for the treatment of relapsing-remitting (RR) MS. Since then, additional agents such as interferon beta-1a, glatiramer acetate (previously copolymer-1), and mitoxantrone hydrochloride have become available for the treatment of patients with MS. These immunomodulatory and immunosuppressive agents, although only partially effective, are beneficial in reducing relapses, preventing disability, and stabilizing magnetic resonance imaging (MRI) changes in patients with MS.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Evidence Summary and Review 2
The Rational Clinical Examination
Other Radiological Modes Including MRI. A comprehensive review of all radiological modes...
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.